Cargando…

Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC

BACKGROUND: In patients with advanced, incurable cancer, anticancer treatment may be used to alleviate cancer-related symptoms, but monitoring of them in daily practice is rarely done. We aim to test the effectiveness of a real-time symptom and syndrome assessment using the E-MOSAIC software install...

Descripción completa

Detalles Bibliográficos
Autores principales: Blum, David, Koeberle, Dieter, Ribi, Karin, Schmitz, Shu-Fang Hsu, Utiger, Urs, Klingbiel, Dirk, Strasser, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517324/
https://www.ncbi.nlm.nih.gov/pubmed/23006802
http://dx.doi.org/10.1186/1472-684X-11-19
_version_ 1782252384445005824
author Blum, David
Koeberle, Dieter
Ribi, Karin
Schmitz, Shu-Fang Hsu
Utiger, Urs
Klingbiel, Dirk
Strasser, Florian
author_facet Blum, David
Koeberle, Dieter
Ribi, Karin
Schmitz, Shu-Fang Hsu
Utiger, Urs
Klingbiel, Dirk
Strasser, Florian
author_sort Blum, David
collection PubMed
description BACKGROUND: In patients with advanced, incurable cancer, anticancer treatment may be used to alleviate cancer-related symptoms, but monitoring of them in daily practice is rarely done. We aim to test the effectiveness of a real-time symptom and syndrome assessment using the E-MOSAIC software installed in handheld computer generating a longitudinal monitoring sheet (LoMoS) provided to the oncologists in a phase III setting. METHODS: In this prospective multicentre cluster randomized phase-III trial patients with any incurable solid tumor and having defined cancer related symptoms, who receive new outpatient chemotherapy in palliative intention (expected tumor-size response rate ≤20%) are eligible. Immediately before the weekly visit to oncologists, all patients complete with nurse assistance the E-MOSAIC Assessment: Edmonton Symptom Assessment Scale, ≤3 additional symptoms, estimated nutritional intake, body weight, Karnofsky and medications for pain and cachexia. Experienced oncologists will be randomized to receive the LoMoS or not. To minimize contamination, LoMoS are removed from the medical charts after visits. Primary endpoint is the difference in global quality of life (items 29 & 30 of EORTC-QlQ-C30) between baseline and last study visit at week 6, with a 10 point between-arm difference considered to be clinically relevant. 20 clusters (=oncologists) per treatment arm with 4–8 patients each are aimed for to achieve a significance level of 5% and a power of 80% in a mixed model approach. Selected co- variables are included in the model for adjustment. Secondary endpoints include patient-perceived patient-physician communication symptom burden over time, and oncologists’ symptom management performance (predefined thresholds of symptoms compared to oncologists’ pharmacological, diagnostic or counselling actions [structured chart review]). DISCUSSION: This trial will contribute to the research question, whether structured, longitudinal monitoring of patients’ multidimensional symptoms, indicators for symptom management, and clinical benefit outcomes can influence patients’ quality of life and symptom distress, in a setting of routine oncology practice. TRIAL REGISTRATION: Current Controlled Trials NCT00477919
format Online
Article
Text
id pubmed-3517324
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35173242012-12-08 Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC Blum, David Koeberle, Dieter Ribi, Karin Schmitz, Shu-Fang Hsu Utiger, Urs Klingbiel, Dirk Strasser, Florian BMC Palliat Care Study Protocol BACKGROUND: In patients with advanced, incurable cancer, anticancer treatment may be used to alleviate cancer-related symptoms, but monitoring of them in daily practice is rarely done. We aim to test the effectiveness of a real-time symptom and syndrome assessment using the E-MOSAIC software installed in handheld computer generating a longitudinal monitoring sheet (LoMoS) provided to the oncologists in a phase III setting. METHODS: In this prospective multicentre cluster randomized phase-III trial patients with any incurable solid tumor and having defined cancer related symptoms, who receive new outpatient chemotherapy in palliative intention (expected tumor-size response rate ≤20%) are eligible. Immediately before the weekly visit to oncologists, all patients complete with nurse assistance the E-MOSAIC Assessment: Edmonton Symptom Assessment Scale, ≤3 additional symptoms, estimated nutritional intake, body weight, Karnofsky and medications for pain and cachexia. Experienced oncologists will be randomized to receive the LoMoS or not. To minimize contamination, LoMoS are removed from the medical charts after visits. Primary endpoint is the difference in global quality of life (items 29 & 30 of EORTC-QlQ-C30) between baseline and last study visit at week 6, with a 10 point between-arm difference considered to be clinically relevant. 20 clusters (=oncologists) per treatment arm with 4–8 patients each are aimed for to achieve a significance level of 5% and a power of 80% in a mixed model approach. Selected co- variables are included in the model for adjustment. Secondary endpoints include patient-perceived patient-physician communication symptom burden over time, and oncologists’ symptom management performance (predefined thresholds of symptoms compared to oncologists’ pharmacological, diagnostic or counselling actions [structured chart review]). DISCUSSION: This trial will contribute to the research question, whether structured, longitudinal monitoring of patients’ multidimensional symptoms, indicators for symptom management, and clinical benefit outcomes can influence patients’ quality of life and symptom distress, in a setting of routine oncology practice. TRIAL REGISTRATION: Current Controlled Trials NCT00477919 BioMed Central 2012-09-24 /pmc/articles/PMC3517324/ /pubmed/23006802 http://dx.doi.org/10.1186/1472-684X-11-19 Text en Copyright ©2012 Blum et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Blum, David
Koeberle, Dieter
Ribi, Karin
Schmitz, Shu-Fang Hsu
Utiger, Urs
Klingbiel, Dirk
Strasser, Florian
Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
title Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
title_full Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
title_fullStr Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
title_full_unstemmed Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
title_short Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
title_sort electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial sakk 95/06 e-mosaic
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517324/
https://www.ncbi.nlm.nih.gov/pubmed/23006802
http://dx.doi.org/10.1186/1472-684X-11-19
work_keys_str_mv AT blumdavid electronicmonitoringofsymptomsandsyndromesassociatedwithcancermethodsofarandomizedcontrolledtrialsakk9506emosaic
AT koeberledieter electronicmonitoringofsymptomsandsyndromesassociatedwithcancermethodsofarandomizedcontrolledtrialsakk9506emosaic
AT ribikarin electronicmonitoringofsymptomsandsyndromesassociatedwithcancermethodsofarandomizedcontrolledtrialsakk9506emosaic
AT schmitzshufanghsu electronicmonitoringofsymptomsandsyndromesassociatedwithcancermethodsofarandomizedcontrolledtrialsakk9506emosaic
AT utigerurs electronicmonitoringofsymptomsandsyndromesassociatedwithcancermethodsofarandomizedcontrolledtrialsakk9506emosaic
AT klingbieldirk electronicmonitoringofsymptomsandsyndromesassociatedwithcancermethodsofarandomizedcontrolledtrialsakk9506emosaic
AT strasserflorian electronicmonitoringofsymptomsandsyndromesassociatedwithcancermethodsofarandomizedcontrolledtrialsakk9506emosaic